Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus

Jeanny B. Aragon‐Ching; S. Gupta; Petros Grivas; S.H. Park; D.P. Petrylak; S.S. Sridhar; Howard Gurney; N. Jacob; K. Tyroller; J. Hoffman; J. Bellmunt

doi:10.1016/j.esmoop.2026.107776

June 12, 2026ESMO OpenOpen Access

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore the long-term outcomes of avelumab as maintenance therapy in advanced urothelial carcinoma patients with high body mass index or diabetes mellitus.
Study with 700 patients assigned to either avelumab plus best supportive care or best supportive care alone.
Assessment of overall survival as the primary endpoint.
Median follow-up of ≥38 months.
Patients with high BMI showed a hazard ratio for overall survival of 0.77 (95% CI 0.49-1.21).
Patients with diabetes mellitus had a hazard ratio for overall survival of 0.60 (95% CI 0.37-0.95).
Long-term safety of avelumab maintenance was consistent with the overall population.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Evaluates long-term survival for advanced urothelial carcinoma in patients with high BMI or diabetes mellitus, indicating benefits of avelumab maintenance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aragon‐Ching et al. (2026) studied this question.

synapsesocial.com/papers/6a2f966ca1cfeec490827c87 https://doi.org/10.1016/j.esmoop.2026.107776

View Full Paper

Ask AI

Bookmark

Share

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading